(NY Post) Hedge fund titan to pocket $3B for 2013

It could be one heckuva New Year’s Eve party for hedge fund titan David Tepper — again.
The founder of Appaloosa Management, with more than $20 billion under management, is looking at a possible $3 billion-plus payday in 2013, which could make him the highest paid hedgie.
That’s quite a feat, especially after Tepper’s 30 percent gain last year earned him $2.2 billion and the top spot on Institutional Investor Alpha’s annual “Rich List” of the top 25 hedge fund managers.
Tepper’s Palomino fund was up 38 percent, after fees, as of Nov. 30, according to an investor, making the 56-year-old one of the few in his business to post a return higher than the 29.1 percent gain of the S&P 500.
Also in the running for highest-paid hedgie is John Paulson, whose $20 billion firm is experiencing a comeback after years of double-digit losses. One of Paulson’s funds has gained 55 percent, but others are still below their high-water mark.
Tepper puts his success down to equal parts good strategy and good karma.
As for strategy in the brave new post-2008 world, he has transformed himself from being one of the savviest distressed debt investors into a top macro investor — or betting on worldwide trends.
For karma, he points to the tens of millions he gave to New Jersey food banks and shelters during the 2008 financial crisis in order to keep them going and the similar efforts made during Hurricane Sandy last year.
His investing perspective was unpopular in the hedge fund world over the past few years, as he refused to buy into the inflation hysteria that led so many managers to attack the Federal Reserve for its quantitative easing. Tepper thought depression was government’s greater concern — and still does. As a result, he didn’t get into the gold mania that cost peers like Paulson dearly.
He also foresaw the bull market that Fed easing would create and started buying bank stocks in late 2008, when other managers thought they could end up being nationalized.
“We always believed in this country,” Tepper told The Post. “We said it in 2008 and 2009 and again and again. We are on the verge of great things.”
That belief is mirrored in his investments in US airline stocks, like Delta Air Lines and United Continental Holdings, which are up 128 percent and 57 percent, respectively, year to date. Airlines accounted for more than $600 million of his portfolio as of Sept. 30.
Appaloosa has an annualized return of 27 percent since Tepper launched it in 1993, shortly after leaving Goldman Sachs.
What’s more, his returns have gotten better as the fund has grown larger, a contrast to the norm. He regularly returns money to investors to keep from getting too big. This year he expects to give back a little less than $2 billion.
As a result, Tepper owns a good chunk of the fund, a percentage he doesn’t disclose.

>>> US Gapping down

Gapping down

M&A news: CTB -5.7% (Cooper Tire Terminates Merger Agreement with Apollo Tyres), VOD -0.6% (takeover of local unit has been approved by Indian regulator, according to reports out).

A few financial related names showing weakness: NBG -3.1%, ING -0.8%, BCS -0.7%, HBC -0.6%.

Metals/mining stocks trading lower: ABX -1.6%, HL -1.4%, NEM -1.2%, GG -1.2%, GDX -1.2%, SLV -1.1%, GLD -1%, AU -0.9%, BBL -0.6%.

Select social media names pulling back: TWTR -1.8%, FB -1.1% (reports out over the weekend indicate FB is losing popularity with UK teens; NYPost discusses that Nasdaq (NDAQ) plans to pay claims related to Facebook IPO at the end of the year), LNKD -0.1%, .

Other news: WPCS -19% (modestly pulling back; disclosed that it received a notice of resignation from CohnReznick LLP, the company's independent registered public accounting firm), MYGN -10.1% (disclosed CMS update - will address a number of both substantive and process concerns; downgraded at JMP and tgt lowered at Piper Jaffray), CWTR -1.3% (extends term of its Chairman to facilitate the Co's ongoing exploration of strategic alternatives), SNY -1.3% (Genzyme receives complete response letter from FDA on Lemtrada; complete response letter informs companies that an application is not ready for approval), BMY -1.2% (still checking), EXPR -1.1% (still checking), LPS -0.9% (RNR to replace Lender Processing Services in the S&P MidCap 400), PHG -0.9% (light volume; still checking), NOK -0.7% (announced that Jesper Ovesen is to step down as Executive Chairman of Nokia Solutions and Networks), GE -0.5% ( issues report on Hudson River project), AAPL -0.5% (Apple disclosed that its Board and management oppose shareholder buyback proposal).

Analyst comments: POZN -2.8% (downgraded to Neutral from Strong Buy at Ascendiant).

>>> Cable & Wireless Communications Discloses Unwind of Monaco disposal pact wi


Cable & Wireless Communications Discloses Unwind of Monaco disposal pact with Bahrain communications group Batelco
- Agreed with Batelco to unwind the previous transfer of a 25% shareholding in Compagnie Monegasque de Communication SAM ("CMC") from CWC to Batelco. CWC has re-paid to Batelco the US$100 million paid by Batelco to CWC upon completion of the Islands disposal and Batelco has re-transferred to CWC the 25% shareholding in CMC. All option arrangements between CWC and Batelco in relation to CMC have terminated.


***Reminder: On Dec 3rd, there were reports that CWC would sell Monaco and Islands unit for $680M in cash to Batelco, with option for another $345M

>>> US Gapping up

Gapping up
Select solar related names showing strength: TSL +8% ( signs investment framework agreement to develop 1GW solar power plant project in Xinjiang, Western China), YGE +2.5%, JASO +1.9%, SOL +0.6% (ReneSola signs Memorandum of Intent to sell three utility-scale projects in China).

A few oil/gas names are modestly higher: WFT +1.1% RIG +0.9%

In the news: CROX +8.8% (Crocs announced that an investment fund affiliated with Blackstone has agreed to purchase $200 mln of newly issued series A convertible preferred stock; CEO McCarvel announced retirement; sees Q4 EPS and revs at low end of prior ranges), PRCP +8.3% (still checking), KNDI +8.2% (continued strength), BIOL +6.5% (ticking higher, Biolase granted canadian license to sell its EPIC 10 soft-tissue diode laser), JDSU +3.6% (still checking), ATHM +3.1% (continued strength), RNR +2.8% (to replace Lender Processing Services in the S&P MidCap 400), PPHM +2.2% (files for $100 mln common and preferred stock offering in S-3 filing; initiates Sunrise pivotal Phase III clinical trial of bavituximab in second-line non-small cell lung cancer), JCP +2.2% (still checking), VVUS +1.4% (received 'generally positive' feedback from CHMP on AQCLAIM/OB-401), BIIB +1% (following WSJ report highlighting cheap stocks), VISN +1% (continued strength), CCL +0.7% (still checking), PPO +0.6% (announces settlement and license agreement with Sumitomo Chemical), WU +0.6% (still checking), KO +0.5% (ticking higher following positive Barron's mention), BITA +0.5% (continued strength), WMT +0.2% (following positive Barron's mention as defensive play of downsizing).

Analyst comments: DIS +0.7% (Disney upgraded to Buy from Neutral at Guggenheim)

(BFW) Sanofi CVR Falls 72% After FDA Rejects MS Drug Lemtrada

+------------------------------------------------------------------------------+

Sanofi CVR Falls 72% After FDA Rejects MS Drug Lemtrada 2013-12-30 13:06:44.627 GMT

By Catherine Larkin Dec. 30 (Bloomberg) -- Sanofi CVR (GCVRZ) falls as much as 72% pre-mkt to 23c. * CVR holders were due to get $1 if Lemtrada won FDA approval before March 31 and as much as $12 more for certain global sales milestones * NOTE: Earlier, Sanofi Multiple Sclerosis Drug Fails to Win FDA Approval; Sanofi Plans to Appeal FDA Decision

For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>

To contact the reporter on this story: Catherine Larkin in Chicago at +1-312-443-5968 or clarkin4@bloomberg.net

To contact the editor responsible for this story: Joanna Ossinger at +1-212-617-7789 or jossinger@bloomberg.net

>>> FB US : According to a study from Global Social Media Impact Study funded by

According to a study from Global Social Media Impact Study funded by the EU, 16-18 yos in UK have moved off Facebook to Snapchat, Instagram and WhatsApp - BBC
- Reason for large decline of teens use on Facebook is they don't want to use something that is now frequented by their parents.
- Head researcher drew attention to his research by putting out the line Facebook, dead, and buried among teenagers.

>>> US Early premarket gappers

Early premarket gappers

Gapping up: PRCP +8.3%, CROX +7.3%, TSL +5.7%, JDSU +3.6%, KNDI +3.1%, ATHM +3.1%, RNR +2.8%, RIG +0.9%, CCL +0.7%, PPO +0.6%, WU +0.6%

Gapping down: WPCS -19%, PPHM -5.8%, NBG -3.1%, ABX -1.6%, CWTR -1.3%, SNY -1.3%, BMY -1.2%, SLV -1.1%, FB -1.1%, EXPR -1.1%, LPS -0.9%, PHG -0.9%, ING -0.8%, BTU -0.8%

(BArron's) A Lion in Winter

A Lion in Winter

The lesson from Sarofim's five decades in the investment business: Buy quality stocks; hold them forever.

After more than five decades in the investment business, Fayez Sarofim remains bullish on U.S. stocks, particularly brand behemoths like Coca-Cola and Philip Morris International that he has owned for decades. Sarofim has long favored well-regarded industry leaders over smaller upstarts.

"People always look for the needle in the haystack. Why not buy the haystack?" says Sarofim, 85, who came here from Egypt in 1946 and founded his Houston-based asset management firm, Fayez Sarofim & Co., 12 years later.

Today, Sarofim runs $30 billion for institutions and individuals, including mutual fund investors, most notably through the $6 billion Dreyfus Appreciation fund (ticker: DGAGX), which his firm subadvises. Over the years he has built a fortune, estimated at more than $2 billion, including an $875 million stake in Kinder Morgan (KMI, the energy-infrastructure giant), a large equity portfolio, and a superb art collection -- including one of the few El Greco paintings in private hands and a raft of abstract expressionists. And, of course, a controlling stake in the Sarofim firm itself.

Fayez Sarofim: "It takes a foreign-born person to appreciate the United States, and the ability of the American people to adapt."
Sarofim's deceptively simple investment philosophy is similar to that of Warren Buffett: Buy great growth companies and don't ever sell. Sarofim and Buffett's Berkshire Hathaway (BRK/A) share similar investments, including Coke (KO), Procter & Gamble (PG) ExxonMobil (XOM), IBM (IBM), and Wal-Mart Stores (WMT). Buffett and Sarofim both recognized that riding dominant companies was a tax-efficient way to build wealth. In fact, much of Sarofim's personal fortune comes from investing the firm's money alongside his clients' for more than 40 years.

Barron's recently met with Sarofim, his son Christopher, 50, and other principals at the firm, which plans to remain private with the same investment approach after Sarofim leaves the scene. The firm has a staff of about 100 people, including 22 investment professionals.

Sarofim, who is known locally as the Sphinx due his Egyptian heritage and few public comments, rarely grants media interviews. Barron's profiled him 16 years ago ("Brand Champion," June 9, 1997).

"It takes a foreign-born person to appreciate the United States, and the ability of the American people to adapt," Sarofim said over lunch at the old-line, wood-paneled Coronado Club in downtown Houston. Like Buffett, Sarofim believes that too much trading is a bad idea. "Nervous energy is a great destroyer of wealth," he says. The firm's portfolio turnover rate is regularly below 20%.

Enlarge Image
image
David Strohl for Barron's
The Sarofim team, from left: Alan Christensen, Christopher Sarofim, Gentry Lee, and Jeff Jacobe.
Sarofim's patriotism reflects his only-in-America success story. "Here's an Egyptian who came here with nothing, went to Harvard Business School, and made a fortune in Houston. Not New York, Houston," says Byron Wien, vice chairman of Blackstone Advisory Partners. "He's a warm and wonderful person. He has a quality that is so critical in business, which is to make you feel important."

Sarofim's view is that companies like Philip Morris International (PM), Coke, Nestlé (NSRGY), and Procter & Gamble offer great ways to play growth in the developing world. An upbeat Sarofim says the S&P 500, now around 1840, can top 2000 next year. "If you have $120 in earnings next year [for the S&P 500] in an environment of low inflation and low interest rates, a price/earnings ratio of 18 to 20 is not unreasonable."

He has a good eye for stocks and arguably an even better one for art. He began buying abstract expressionists and pop art in the 1960s, and his downtown Houston office is home to a fabulous collection, including hundreds of paintings and other works from artists such as Robert Motherwell, Willem de Kooning, Robert Rauschenberg, and Jasper Johns. He also owns works by Mary Cassatt and Eugène Delacroix. Hanging amid more than a dozen paintings in his office could be his most valuable work, a small El Greco masterpiece from the late 16th century, The Crucifixion.

SAROFIM'S FIRM has a good long-term record, but it's way behind the S&P 500 this year, after trailing the index in 2012. The Dreyfus Appreciation fund, which is representative of the firm's portfolio, is up 20% through Dec. 24, 11 percentage points behind the S&P. Most of Sarofim's big holdings, including Philip Morris International, Coke, and ExxonMobil, are lagging the benchmark.

This doesn't faze Sarofim and his associates. "We've underperformed four times in the past 25 years, and in each of the past three, we have outperformed strongly after those periods. We've stuck to our knitting, and that has worked well over time," says Jeff Jacobe, the firm's director of investments.

Jacobe says the firm's portfolio "is cheap on an absolute and relative basis" with a higher dividend, better growth prospects, lower leverage, and lower price/earnings ratio than the overall market. He argues that the Sarofim portfolio is at "its cheapest relative valuation since the 1980s."

Over the past 20 years, the firm's accounts are nearly a percentage point ahead of the S&P 500, based on annualized performance, but that doesn't include fees. The Dreyfus Appreciation fund, up 8.9% annually since 1993, is slightly behind the index, reflecting its expense ratio of about one percentage point, according to Morningstar.

ONE INVESTMENT THAT SAROFIM never made was in Enron, the Houston energy outfit that collapsed into bankruptcy after financial fraud was uncovered in 2001. "They tried hard to get us to invest," Sarofim said, referring to former Enron executives Ken Lay and Jeffrey Skilling. Sarofim said he could never get comfortable with Enron's financials. "They said they'd get bigger than Exxon. We said we'd rather own Exxon."

Critics would argue that Sarofim's portfolio, which hasn't changed much since Barron's wrote about it in 1997, amounts to an outdated growth-stock portfolio with little exposure to the dynamic companies that have powered the stock market in recent years, such as Google, Amazon.com, and Visa, as well as biotechnology firms like Biogen. For all of Coke's power, given its global beverage-distribution network, its shares still are below their 1998 peak, as the company grapples with weakening soda markets in the developed world.

Jacobe responds that Sarofim looks at everything in the growth universe but that some of the marquee stocks haven't made the cut. "To us, the duration of growth over the long term is more important than the rate of growth in any year," says Jacobe. The firm did add Apple (AAPL) about six years ago. It is now overweight in consumer staples and energy relative to the S&P 500, and underweight in financials, with no exposure to telecommunications and electric utilities.

The firm's assets under management are way below their peak of $59 billion in 1999, reflecting institutional outflows. Around that time, Sarofim reportedly came close to selling the firm to European banks for about $900 million, which is probably double what it's worth now.

Brand Champion

Fayez Sarofim has long favored large multinationals with strong balance sheets.

Sarofim's Top 10 Holdings Percent of Portfolio *
Philip Morris Intl / PM 5.9%
Apple / AAPL 5.3
ExxonMobil / XOM 4.6
Coca-Cola / KO 4.3
Chevron / CVX 3.7
Nestlé / NSRGY 2.9
Johnson & Johnson / JNJ 2.8
McDonald's / MCD 2.8
ConocoPhillips / COP 2.6
IBM / IBM 2.6
*As of Sept. 30 Source: Fayez Sarofim & Co.
SAROFIM RECOGNIZED IN THE 1960s and 1970s the power of globally dominant companies. "They have the flexibility and critical mass to invest in developing countries," Sarofim says. A prime example is one of the firm's longest-standing holdings: Philip Morris, which Sarofim bought 50 years ago.

Back then, he recalls, Philip Morris had no international business, and its key cigarette brand, Marlboro, had just a 9% domestic market share, way below its 43% market share now. Cigarette cash flows were so strong as Marlboro grew over the years that Philip Morris was able to expand overseas and gobble up food companies, including Kraft. Sarofim now owns all four companies that have come out of the original Philip Morris: Altria (MO), Kraft Foods (KRFT), Mondelez International (MDLZ), and Philip Morris International, now the world's largest investor-owned tobacco company.

He's in the office most days, and when he's not, he checks in with his former assistant, Raye White, a member of the firm's investment committee who has been with him since the beginning. Sarofim gave up tennis when he turned 65, but often swims at his home in the exclusive River Oaks section of Houston. Dressed formally in a three-piece, blue pinstripe suit and red patterned tie, Sarofim enjoyed a cigar and several cups of espresso after lunch at the Coronado Club while discussing the firm's history and investment style.

Sarofim recalls that Houstonians called him "a fly by night" after he opened his doors in 1958. At that time, there were few independent equity management firms, let along one run by a 30-year-old Egyptian with no real track record. The investment business then was dominated by New York banks and Boston firms like Loomis Sayles and Scudder Stevens & Clark.

Sarofim's fortunes began to turn in the early 1960s, when he married Louisa Stude, the adopted daughter of Herman Brown, a founder of the Brown & Root construction company, now part of Halliburton. At that time, Brown & Root had close ties to the most powerful man in Texas, Vice President Lyndon Johnson.

The Brown family was well connected in Houston, and Sarofim soon was running money for the Rice University endowment, which remains a client of the firm. Sarofim has had two marriages and two messy divorces that were chronicled in the local media. He's unmarried now. He quips that one reason he never became an activist investor is that he "wanted to stay out of the newspapers."

As one of Houston's wealthiest men, Sarofim has given money to range of organizations, as well as participating in a group that brought back to the city a pro football team, the Houston Texans, after the Oilers left town for Tennessee. That 2002 investment, which he jokingly called a "civic duty," has turned out well, with the NFL team now valued at more than $1 billion, 50% more than what the franchise cost. Another shrewd investment that Sarofim made personally was participating in the leveraged buyout of Kinder Morgan.

Sarofim plans to continue working for as long as he can. "I'm like Buffett," he says, "retirement is not in my vocabulary." But his succession plans are in place. His son Christopher, who has been with the firm since 1988 and now is vice chairman, will follow him as chairman. Other firm veterans, including Jacobe; the current president, Gentry Lee; and the chief operating officer, Alan Christensen, will play key roles.

Transition isn't easy for an investment firm closely associated with an aging leader whose name is on the door. Yet, the firm appears to be in a good position to successfully outlive its founder. Better performance certainly would help. That prospect looks like a reasonable bet, given the quality of Sarofim's investments and the firm's history of recovery after rocky periods.